HIV prevention drug could reduce cases globally but USAID cuts prevent access, say experts

What happened

According to The Guardian’s linked report, HIV prevention drug could reduce cases globally but USAID cuts prevent access, say experts, Injectable PrEP drug holds promise but investment in HIV prevention has declined dramatically worldwide Sign up for the Breaking News US newsletter email New innovations in HIV prevention could dramatically reduce the number of new HIV cases around the globe, but US foreign aid cuts will mean that those that most need the new medication will be unable to access it, according to experts at the Aids 2026 Conference in Rio de Janeiro, Brazil . One year ago, the World Health Organization recommended that governments around the world prioritize expanded access to lenacapavir, an injectable version of the HIV prevention medication PrEP that requires only two injections annually. PrEP, which also comes in the form of daily oral medications and bimonthly injections, is 99% effective in preventing sexually transmitted HIV for people who take it consistently. Continue reading…

Context

The development sits in VINI’s Technology coverage for readers following technology, science, product policy, markets, infrastructure, and the public consequences of innovation. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The linked report is dated 2026-07-31T16:29:14+00:00.

What to watch

Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.

Source

Primary source: HIV prevention drug could reduce cases globally but USAID cuts prevent access, say experts via The Guardian. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.